Active — Not RecruitingNot Applicable

Liver Fibrosis in Zambian HIV-HBV Co-infected Patients

Zambia303 participantsStarted 2015-10

Plain-language summary

A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to identify the risk factors for major endpoints of interest, including HCC and HBV functional cure. This cohort will also create a pool of potential participants for in-depth mechanistic studies and clinical trials of novel HBV cure drugs.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older * Living with HIV infection * Living with active HBV infection, defined as any single positive HBsAg assay * Naïve to antiretroviral therapy or currently participating in HIV/HBV co-infection in IeDEA-SA Exclusion Criteria: * Unable or unwilling to provide informed consent * Planning to relocate out of Lusaka district

What they're measuring

Change in liver fibrosis stage

Timeframe: From baseline to 10 years of follow-up

Trial details

NCT IDNCT02344680

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-04

View on ClinicalTrials.gov More Human Immunodeficiency Virus trials